The in vivo CAR-T buildout continued as CREATE Medicines (previously Myeloid Therapeutics) secured a $122 million Series B to fund early development of autoimmune and cancer candidates. The round, backed by Newpath Partners and other investors, supports the startup’s push through early human testing stages. The financing highlights continued appetite for immune-cell engineering that aims to reduce the manufacturing burden of conventional ex vivo CAR-T. It also suggests companies are prioritizing programs that can show actionable early signals across multiple disease categories. For the sector, the $122 million round reinforces that in vivo CAR-T is still attracting capital even as clinical differentiation hinges on safety and controllability data in the first patients.